BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34615547)

  • 41. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
    Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
    Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
    Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
    Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
    PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
    Encinas G; Maistro S; Pasini FS; Katayama ML; Brentani MM; Bock GH; Folgueira MA
    Rev Assoc Med Bras (1992); 2015; 61(5):474-83. PubMed ID: 26603012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
    Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
    Mahdi H; Xiu J; Reddy SK; DeBernardo R
    J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.
    Steffensen KD; Waldstrøm M; Grove A; Lund B; Pallisgård N; Jakobsen A
    Int J Gynecol Cancer; 2011 Dec; 21(9):1592-600. PubMed ID: 21926912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
    BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An in vivo model for the study of ovarian cancer and the persistence of characteristic mutations in xenografts.
    Li Y; Gu YJ; Liu CN; Yue TF
    Eur J Gynaecol Oncol; 2014; 35(4):387-92. PubMed ID: 25118479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
    Xing D; Zheng G; Schoolmeester JK; Li Z; Pallavajjala A; Haley L; Conner MG; Vang R; Hung CF; Wu TC; Ronnett BM
    Am J Surg Pathol; 2018 Jun; 42(6):750-760. PubMed ID: 29505425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
    Kurman RJ; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 60. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
    Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
    Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.